Background {#Sec1}
==========

Parkinson's disease (PD) is a heterogeneous neurodegenerative disorder with diverse clinical manifestations that include both motor and non-motor symptoms \[[@CR1]\]. Cardinal motor symptoms used for diagnosing PD include bradykinesia, which is one of the most important features, as well as rigidity, resting tremor, and postural instability \[[@CR2]\]. Since tremor may have a different pathophysiology than bradykinesia and rigidity \[[@CR3]\], the response of tremor to dopaminergic agents is less clear than that of bradykinesia or rigidity \[[@CR4]\].

Previous epidemiological studies established that coffee is a negative risk factor for PD \[[@CR5]--[@CR8]\]. This is further supported by a study showing that caffeine, a major chemical component of coffee, attenuates the loss of striatal dopamine and dopamine transporter binding sites in an experimental PD mouse model \[[@CR9]\]. Additional experimental and observational PD studies demonstrated that coffee consumption had a beneficial effect on PD motor symptoms \[[@CR10], [@CR11]\]. Since coffee consumption reduces the risk of PD, there might be a relationship between coffee consumption and the severity of motor symptoms. However, few studies have investigated the relationship between coffee consumption and PD motor symptoms.

Gender differences in PD phenotypic presentation and disease progression are widely accepted, and the impact of caffeine on PD differs based on gender \[[@CR5], [@CR12]--[@CR15]\]. In addition, the association between coffee consumption and the severity of motor symptoms may differ between genders. Therefore, in the current study, we investigated the association between coffee consumption and motor symptoms in de novo PD patients based on their gender.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

We performed a baseline survey to determine the association between coffee consumption and motor symptoms in a cohort of newly diagnosed, treatment-naïve, early-stage PD patients consisting of 284 participants. All participants were enrolled from the outpatient clinic at the Chonnam National University Hospital and were recruited consecutively from January 2011 to December 2016.

Parkinsonism comprises multiple syndromes including PD. Thus, according to the international criteria, both parkinsonism and PD symptoms must be evaluated to make a proper PD diagnosis \[[@CR2]\]. Parkinsonism is defined by the presence of bradykinesia and one additional symptom, including 4--6 Hz rest tremor, muscular rigidity, or postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction, according to a previous study \[[@CR2]\]. The United Kingdom Parkinson's Disease Society Brain Bank clinical diagnostic criteria were used for the clinical diagnosis of PD \[[@CR2]\]. An additional inclusion criterion for our study was the lack of significant cerebral lesions, as assessed by brain magnetic resonance imaging (MRI). None of the patients had a history of taking either antiparkinsonian or antidopaminergic agents. In contrast, the exclusion criteria were an uncertain diagnosis, secondary or atypical parkinsonism according to the recent clinical diagnostic criteria \[[@CR16]--[@CR19]\], failure to complete the coffee consumption questionnaire, and dementia. The time at which one of the four cardinal PD signs was first noted by the patient or caregiver was defined as the onset of PD.

All participants provided written informed consent. The study was approved by the Institutional Review Board of the hospital and was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki.

Clinical evaluation {#Sec4}
-------------------

All PD patients were diagnosed by a specialist in movement disorders (S.M.Choi). The history of the patient and a neurological examination were used to obtain detailed clinical information, prior to the administration of antiparkinsonian medication.

Participants underwent a thorough neurological examination and were asked about the age at symptom onset and duration of formal education, as well as past and current medications. Both the severity and stage of the parkinsonism were evaluated using the modified Hoehn and Yahr (mHY) staging scale and Unified Parkinson's Disease Rating Scale (UPDRS) motor (part III) and activities of daily living (ADL; part II) sub-scores. The effect of coffee consumption on the sum of each motor symptom score in the UPDRS, in addition to postural instability and gait disturbance (PIGD) and akinetic-rigid (AR) scores, was evaluated. Patients were scored for these variables using the methods proposed by both Jankovic at al. and Kang et al. \[[@CR20], [@CR21]\]. In short, in Jankovic's method, the tremor score was calculated by dividing the sum of the UPDRS III items 20 and 21 and UPDRS II item 16 by 8, whereas the PIGD score was calculated by dividing the sum of the UPDRS III items 29 and 30 and UPDRS II items 13--15 by 5 \[[@CR20], [@CR22]\]. In contrast, in Kang's method, the tremor score was calculated by dividing the sum of the UPDRS III items 20 and 21 by 4, and the AR score was calculated by dividing the sum of the UPDRS III items 22--27 and 31 by 15 \[[@CR21]\].

To evaluate non-motor PD symptoms and general cognition, the Korean versions of the Mini-Mental State Examination (K-MMSE) and the Montreal Cognitive Assessment (MoCA-K) were used \[[@CR23], [@CR24]\]. Additionally, the Non-Motor Symptoms assessment scale for PD (NMSS) and the Beck Depression Inventory (BDI) were used \[[@CR25], [@CR26]\].

Data on past and present coffee consumption were obtained via a semi-structured interview. In brief, the interview had the following questions: 1) Have you ever had coffee or do you currently drink coffee? 2) If you have ever drunk coffee, when did you start drinking coffee? 3) How long have you been drinking coffee? 4) On average, how many cups of coffee do you drink per day? 5) If you have stopped drinking coffee, when did you stop drinking coffee? For the analyses, we allocated our participants to two groups, the coffee drinker and non-coffee drinker group.

Statistical analysis {#Sec5}
--------------------

The results are presented as the mean ± standard deviation (SD) for continuous variables while numbers and percentages are provided for categorical variables. Comparisons of the demographic and clinical variables between PD patients with and without a history of drinking coffee were conducted using bivariate analyses (Student's t-test or chi-square test, depending on the data distribution). Adjustments were made for the variables when bivariate analyses revealed a significant difference between coffee and non-coffee drinkers. Comparison of the severity of motor and non-motor scores between PD patients with and without a history of drinking coffee was conducted using analysis of covariance (ANCOVA), which controlled for the significantly different demographic and clinical variables. We further evaluated the dose-dependent effect of the amount of coffee consumption in a day. Additionally, such analyses were performed in each gender subgroup to investigate the gender differences underlying the association. The *p*-values for the motor score on UPDRS and motor score on subtypes were corrected for by multiple testing using the false discovery rate. All statistical analyses were performed using the SPSS software for Windows (version 22.0, IBM corp., Armonk, NY, USA). A *p*-value \< 0.05 was considered statistically significant.

Results {#Sec6}
=======

Comparison between coffee and non-coffee drinkers {#Sec7}
-------------------------------------------------

Of the 284 de novo PD patients enrolled (Table [1](#Tab1){ref-type="table"}), a total of 204 patients (71.83%) and 80 patients (28.17%) were categorized as coffee drinkers (coffee drinker group) and non-coffee drinkers (non-coffee drinker group), respectively. The coffee drinker group comprised current coffee drinkers and those who have had coffee in the past but have now stopped. Most of the patients who quit drinking coffee had a history of coffee drinking for more than 10 years. As shown in Table [2](#Tab2){ref-type="table"}, intergroup comparisons revealed that coffee drinkers were younger, included more men, younger in age at cardinal motor symptom onset, and reported more years in formal education than the non-coffee drinkers. When comparing motor- and ADL-related scores, coffee drinkers had significantly lower UPDRS motor scores (*p* = 0.020) as well as tremor (*p* = 0.002), bradykinesia (*p* = 0.022), and gait and posture (*p* = 0.022) scores than non-coffee drinkers. When the tremor was divided into rest and action tremors, only rest tremor (*p* = 0.001) showed a significant difference. Furthermore, the univariate analysis revealed that coffee drinkers had significantly lower tremor scores (*p* = 0.001 for Jankovic's method, *p* = 0.002 for Kang's method) than non-coffee drinkers. However, PIGD and AR scores were not significantly different between the two groups. When comparing non-motor scores, we found that coffee drinkers had higher MMSE (*p* = 0.005), but lower BDI (*p* = 0.005) and total NMSS (*p* = 0.007) scores than non-coffee drinkers. Table 1Demographics and clinical characteristics of patients with Parkinson's disease (*N* = 284)Age (years)65.76 ± 9.63Sex (female:male)137:147Age at symptom onset (years)63.82 ± 9.69Duration of disease (months)21.98 ± 26.13Formal education (years)7.77 ± 5.17Modified H-Y stage1.79 ± 0.80UPDRS motor score20.37 ± 10.65UPDRS ADL score7.35 ± 5.63MMSE25.49 ± 3.84MoCA23.69 ± 4.74BDI12.42 ± 9.44NMSS score53.27 ± 46.67The values represent the mean ± standard deviation for continuous variables and numbers for categorical variables*H-Y* Hoehn and Yahr, *UPDRS* Unified Parkinson's disease rating scale, *ADL* Activities of daily living, *MMSE* Mini-Mental State Examination, *MoCA* Montreal Cognitive Assessment, *BDI* Beck Depression Inventory, *NMSS* Non-Motor Symptoms assessment scale for Parkinson's disease Table 2Comparison of Parkinson's disease characteristics between coffee drinkers and non-coffee drinkersCoffee drinker\
(*n* = 204)Non-coffee drinker\
(*n* = 80)*p*-valueAdjusted\
*p*-valueDemographic Age (years)64.57 ± 9.8368.79 ± 8.240.001 Sex (female:male)84:12053:27\<  0.001 Age at symptom onset (years)62.84 ± 10.0067.00 ± 8.150.001 Disease duration (months)21.08 ± 24.2322.04 ± 22.65NS Formal education (years)8.54 ± 5.305.77 ± 4.28\<  0.001Motor and ADL Modified H-Y stage1.75 ± 0.801.89 ± 0.84NS UPDRS motor score19.46 ± 9.9722.84 ± 12.040.020NS\* UPDRS ADL score7.02 ± 5.248.22 ± 6.60NSMotor scores on UPDRS Tremor2.48 ± 2.173.64 ± 2.900.002\<  0.001\*† Rest tremor (Item 20)1.49 ± 1.672.41 ± 2.230.0010.001\*† Action tremor (Item 21)0.99 ± 1.251.23 ± 1.45NSNS\* Bradykinesia8.93 ± 5.3610.83 ± 6.280.022NS\* Rigidity4.60 ± 2.834.92 ± 2.99NS Gait and Posture0.78 ± 1.191.16 ± 1.270.022NS\*Motor scores on subtypes Tremor score (Jankovic)0.44 ± 0.320.61 ± 0.410.001\<  0.001\*† PIGD score (Jankovic)0.41 ± 0.470.47 ± 0.52NS Tremor score (Kang)0.62 ± 0.540.91 ± 0.720.002\<  0.001\*† Akinetic-Rigid score (Kang)0.90 ± 0.511.05 ± 0.59NSNon-motor symptoms MMSE25.88 ± 3.7124.38 ± 4.000.005NS\*\* MoCA23.99 ± 4.6322.31 ± 5.04NS BDI11.32 ± 8.3515.47 ± 11.510.005NS\*\* Total NMSS score48.80 ± 46.1265.72 ± 46.240.007NS\*\*NS, statistically not significant\* Adjusted *p*-values were calculated by ANCOVA after adjustment for age, sex, age at symptom onset, formal education period, MMSE, BDI and total NMSS score\*\* Adjusted *p*-values were calculated by ANCOVA after adjustment for age, sex, age at symptom onset, formal education period, and UPDRS motor score† Means statistically significant after correcting for multiple testing using the false discovery rate

After adjustment for significant clinical variables found in the univariate analysis, we found that rest tremor score (*p* = 0.001) on UPDRS and tremor scores on Jankovic's and Kang's methods (all *p*-values \< 0.001) were lower in coffee drinkers than in non-coffee drinkers. However, scores related to other motor manifestations, such as bradykinesia, gait and posture, PIGD, and AR, were not significantly different between the two groups. Furthermore, after adjustment, there was no significant difference between the two groups for all the non-motor symptom scores (Table [2](#Tab2){ref-type="table"}).

Since the prevalence of coffee consumption differed according to gender, we compared the demographic and clinical variables between coffee drinkers and non-coffee drinkers in each gender. Similar to the results described above, rest tremor scores were lower in coffee drinkers than in non-coffee drinkers in both the male and female subgroups, after adjusting for the significant variables found in the univariate analysis (Table [3](#Tab3){ref-type="table"}). Table 3Comparison of Parkinson's disease characteristics between coffee drinkers and non-coffee drinkers across gendersMaleFemaleCoffee drinker\
(*n* = 120)Non-coffee drinker\
(*n* = 27)*p*-valueAdjusted *p*-valueCoffee drinker\
(*n* = 84)Non-coffee drinker\
(*n* = 53)*p*-valueAdjusted *p*-valueDemographic Age (years)64.36 ± 10.0472.20 ± 6.05\<  0.00165.01 ± 9.4567.32 ± 8.82NS Age at symptom onset (years)62.63 ± 10.1469.75 ± 6.24\<  0.00163.29 ± 9.7165.53 ± 8.62NS Disease duration (months)21.00 ± 26.5129.36 ± 43.61NS21.21 ± 20.6922.02 ± 21.93NS Formal education (years)10.15 ± 5.187.74 ± 4.66NS6.16 ± 4.504.94 ± 3.80NSMotor and ADL Modified H-Y stage1.75 ± 0.742.00 ± 0.78NS1.72 ± 0.831.82 ± 0.86NS UPDRS motor score19.47 ± 8.5024.13 ± 11.690.024NS\*18.99 ± 11.2622.22 ± 12.27NS UPDRS ADL score7.15 ± 5.248.84 ± 6.03NS6.66 ± 5.177.98 ± 6.86NSMotor scores on UPDRS Tremor2.52 ± 2.424.28 ± 3.460.0210.002\*†2.44 ± 1.763.32 ± 2.550.0180.036\* Rest tremor (Item 20)1.43 ± 1.832.84 ± 2.660.0170.004\*1.57 ± 1.412.20 ± 1.980.0340.044\* Action tremor (Item 21)1.08 ± 1.281.08 ± 1.44NSNS\*0.86 ± 1.201.12 ± 1.38NSNS\* Bradykinesia8.60 ± 4.4810.72 ± 5.820.043NS\*9.40 ± 6.4010.88 ± 6.56NS Rigidity4.71 ± 2.705.00 ± 3.30NS4.44 ± 3.004.88 ± 2.85NS Gait and Posture0.68 ± 1.011.20 ± 1.000.020NS\*0.93 ± 1.401.14 ± 1.40NSMotor scores on subtypes Tremor score (Jankovic)0.45 ± 0.350.68 ± 0.480.0060.005\*†0.42 ± 0.270.58 ± 0.370.0070.026\*† PIGD score (Jankovic)0.38 ± 0.450.45 ± 0.48NS0.46 ± 0.490.48 ± 0.54NS Tremor score (Kang)0.63 ± 0.611.07 ± 0.860.0210.002\*†0.61 ± 0.440.83 ± 0.640.0180.036\*† Akinetic-Rigid score (Kang)0.89 ± 0.441.05 ± 0.57NS0.92 ± 0.601.05 ± 0.60NSNon-motor symptoms MMSE26.41 ± 3.4725.67 ± 3.13NS25.11 ± 3.9223.79 ± 4.24NS MoCA24.20 ± 4.0323.18 ± 4.35NS23.55 ± 5.4921.87 ± 5.51NS BDI10.43 ± 7.9111.04 ± 9.08NS12.56 ± 8.8317.68 ± 12.020.0100.018\*\* Total NMSS score52.26 ± 51.3659.76 ± 39.25NS43.95 ± 37.3068.70 ± 49.470.0030.009\*\*NS, statistically not significant\* Adjusted *p*-values were calculated by ANCOVA after adjustment for age, age at symptom onset, formal education period, MMSE, BDI and total NMSS score\*\* Adjusted *p*-values were calculated by ANCOVA after adjustment for age, age at symptom onset, formal education period, and UPDRS motor score† Means statistically significant after correcting for multiple testing using the false discovery rate

Dose-dependent relationship between coffee consumption and PD symptoms {#Sec8}
----------------------------------------------------------------------

The median value of coffee consumption was one cup a day; therefore, PD patients were categorized as non-coffee drinkers, coffee drinkers - one cup a day, and coffee drinkers - more than one cup a day, to evaluate the dose-dependent effect of the coffee consumption on tremor. We found that mHY stage, UPDRS motor, UPDRS tremor, UPDRS rest tremor, UPDRS bradykinesia, UPDRS gait and posture, tremor scores in both the Jankovic's and Kang's methods, and the AR score in Kang's method were inversely related to the number of cups of coffee per day, and this was significant. Additionally, we found a significant inverse relationship between the BDI score and the number of cups of coffee per day, although MMSE and MoCA scores were directly related to the number of cups of coffee per day. However, after adjustment for the confounders, only tremor scores (UPDRS tremor, UPDRS rest tremor, and tremor scores in both Jankovic's and Kang's methods) were found to be related to coffee consumption in a dose-dependent manner (Table [4](#Tab4){ref-type="table"}). Table 4Comparisons of demographic and clinical characteristics among Parkinson's disease patients categorized by coffee drinking status (Non-coffee drinker, Coffee drinker - 1 cup a day, Coffee drinker - more than 1 cup a day \[median = 1\])Non-coffee drinker\
(*n* = 80)Coffee drinker 1 cup\
(*n* = 99)Coffee drinker more than 1 cup\
(*n* = 105)*p*-value*P* for trendAdjusted *p*-valueDemographic Age (years)68.79 ± 8.2466.52 ± 8.9762.52 ± 10.22\<  0.001\<  0.001 Sex (female:male)53:2748:5136:69\<  0.001\<  0.001 Age at symptom onset (years)67.00 ± 8.1564.85 ± 8.9460.80 ± 10.56\<  0.001\<  0.001 Disease duration (months)22.04 ± 22.6520.40 ± 19.1620.93 ± 27.00NSNS Formal education (years)5.77 ± 4.288.15 ± 4.868.92 ± 5.53\<  0.001\<  0.001Motor and ADL Modified H-Y stage1.89 ± 0.841.82 ± 0.721.66 ± 0.82NS0.028NS\* UPDRS motor score22.84 ± 12.0420.9 ± 9.617.9 ± 9.90.0060.002NS\* UPDRS ADL score8.22 ± 6.607.0 ± 5.56.8 ± 5.2NSNSMotor scores on UPDRS Tremor3.64 ± 2.902.56 ± 2.372.40 ± 2.070.0030.0010.002\*† Rest tremor (Item 20)2.41 ± 2.231.77 ± 1.431.41 ± 1.730.001\<  0.0010.002\*† Action tremor (Item 21)1.23 ± 1.451.30 ± 1.400.90 ± 1.200.0760.074NS\* Bradykinesia10.83 ± 6.289.61 ± 5.728.89 ± 5.220.0370.012NS\* Rigidity4.92 ± 2.995.13 ± 2.964.28 ± 2.75NSNS Gait and Posture1.16 ± 1.270.90 ± 1.070.68 ± 1.270.0150.004NS\*Motor scores on subtypes Tremor score (Jankovic)0.60 ± 0.410.45 ± 0.350.43 ± 0.280.0040.0010.003\*† PIGD score (Jankovic)0.47 ± 0.520.43 ± 0.470.38 ± 0.50NSNS Tremor score (Kang)0.89 ± 0.720.64 ± 0.590.60 ± 0.500.0030.0010.002\*† Akinetic-Rigid score (Kang)1.04 ± 0.600.95 ± 0.520.85 ± 0.48NS0.018NS\*Non-motor symptoms MMSE24.38 ± 4.0025.3 ± 3.726.2 ± 3.70.009\<  0.001NS\*\* MoCA22.31 ± 5.0422.7 ± 5.225.1 ± 3.60.0010.001NS\*\* BDI15.47 ± 11.5111.66 ± 7.9011.00 ± 8.840.0060.003NS\*\* Total NMSS score65.72 ± 46.2448.25 ± 47.2550.48 ± 45.88NSNS\* Adjusted *p*-values were calculated by ANCOVA after adjustment for age, sex, age at symptoms onset, formal education period, MMSE, MoCA, and BDI\*\* Adjusted *p*-values were calculated by ANCOVA after adjustment for age, sex, age at symptom onset, formal education period, and UPDRS motor score† Means statistically significant after correcting for multiple testing using the false discovery rate

Finally, we evaluated the dose-dependent effect of coffee consumption on tremor in each gender. Tremor scores (UPDRS tremor, UPDRS rest tremor, and tremor scores in both the Jankovic's and Kang's methods) had an inverse relationship with coffee consumption in a dose-dependent manner only in the male subgroup, after adjustment for significant clinical variables found in the univariate analysis (Table [5](#Tab5){ref-type="table"}). Table 5Comparisons of demographic and clinical characteristics among Parkinson's disease patients categorized by coffee drinking status between genders (Non-coffee drinker, Coffee drinker - 1 cup a day, Coffee drinker - more than 1 cup a day \[median = 1\])MaleFemaleNon-coffee drinker\
(*n* = 27)Coffee drinker 1 cup\
(*n* = 51)Coffee drinker more than 1 cup\
(*n* = 69)*p*-valuep for trendAdjusted *p*-valueNon-coffee drinker\
(*n* = 53)Coffee drinker 1 cup\
(*n* = 48)Coffee drinker more than 1 cup\
(*n* = 36)*p*-value*p* for trendAdjusted *p*-valueDemographic Age (years)72.04 ± 6.0067.29 ± 9.0862.03 ± 10.26\< 0.001\< 0.00167.62 ± 8.6865.69 ± 8.8963.47 ± 10.22NS0.038 Age at symptom onset (years)69.68 ± 6.1765.72 ± 8.7860.17 ± 10.54\< 0.001\< 0.00165.69 ± 8.5163.94 ± 9.1162.01 ± 10.63NS0.070 Disease duration (months)28.30 ± 42.0818.98 ± 20.1222.69 ± 30.81NSNS23.79 ± 25.2621.98 ± 18.1317.61 ± 17.65NSNS Formal education (years)8.11 ± 4.889.78 ± 5.2710.31 ± 5.14NSNS4.73 ± 3.856.61 ± 3.895.93 ± 5.23NSNSMotor and ADL Modified H-Y stage1.93 ± 0.791.94 ± 0.731.64 ± 0.72NSNS1.84 ± 0.861.70 ± 0.701.71 ± 0.98NSNS UPDRS motor score23.18 ± 11.7122.28 ± 9.1217.78 ± 7.600.0070.010NS\*22.40 ± 12.2719.50 ± 10.4717.80 ± 12.08NSNS UPDRS ADL score8.67 ± 5.867.63 ± 5.776.81 ± 4.88NSNS8.21 ± 6.726.27 ± 4.826.72 ± 5.64NSNSMotor scores on UPDRS Tremor4.15 ± 3.362.55 ± 2.822.49 ± 2.140.0170.0060.014\*†3.26 ± 2.572.58 ± 1.752.25 ± 1.70NS0.026NS\* Rest tremor (Item 20)2.84 ± 2.661.62 ± 1.471.39 ± 1.920.0060.0010.016\*†2.20 ± 1.981.95 ± 1.401.45 ± 1.41NS0.017NS\* Action tremor (Item 21)1.44 ± 1.581.46 ± 1.500.98 ± 1.21NSNS1.12 ± 1.381.10 ± 1.260.79 ± 1.18NSNS Bradykinesia10.26 ± 5.858.96 ± 5.108.45 ± 3.99NSNS11.00 ± 6.659.49 ± 6.038.97 ± 6.73NSNS Rigidity4.81 ± 3.275.42 ± 3.104.25 ± 2.26NSNS4.91 ± 2.994.63 ± 2.684.11 ± 3.21NSNS Gait and Posture1.15 ± 0.990.88 ± 1.130.54 ± 0.900.0180.008NS\*1.21 ± 1.450.85 ± 1.130.92 ± 1.63NSNSMotor scores on subtypes Tremor score (Jankovic)0.66 ± 0.460.46 ± 0.410.44 ± 0.300.0320.0110.027\*0.57 ± 0.380.44 ± 0.280.41 ± 0.250.0350.020NS\* PIGD score (Jankovic)0.42 ± 0.470.44 ± 0.520.34 ± 0.40NSNS0.49 ± 0.550.43 ± 0.430.48 ± 0.56NSNS Tremor score (Kang)1.04 ± 0.840.64 ± 0.710.63 ± 0.530.0170.0060.014\*†0.82 ± 0.640.65 ± 0.440.56 ± 0.42NS0.026NS\* Akinetic-Rigid score (Kang)1.00 ± 0.570.96 ± 0.510.85 ± 0.37NSNS1.06 ± 0.610.94 ± 0.540.87 ± 0.64NS0.147Non-motor symptoms MMSE25.80 ± 3.1425.88 ± 3.8026.76 ± 3.20NSNS23.78 ± 4.1625.12 ± 3.3225.24 ± 4.69NSNS MoCA23.22 ± 4.2223.34 ± 4.6824.82 ± 3.44NSNS21.58 ± 5.5722.26 ± 5.5925.62 ± 4.070.0160.009NS\*\* BDI10.82 ± 8.8310.80 ± 7.6510.23 ± 8.22NSNS17.45 ± 11.8412.56 ± 8.1412.47 ± 9.880.0240.025NS\*\* Total NMSS score57.41 ± 39.2653.61 ± 58.4051.97 ± 46.36NSNS66.08 ± 49.2442.56 ± 31.0547.61 ± 45.450.0170.0470.044\*\*NS, statistically not significant\* Adjusted *p*-values were calculated by ANCOVA after adjustment for age, age at symptoms onset, formal education period, MMSE, MoCA, and BDI\*\* Adjusted *p*-values were calculated by ANCOVA after adjustment for age, age at symptom onset, formal education period, and UPDRS motor score† Means statistically significant after correcting for multiple testing using the false discovery rate

Discussion {#Sec9}
==========

This study investigated the relationship between coffee consumption and motor symptoms in de novo PD patients. In summary, we found that 1) coffee drinkers have lower tremor scores than non-coffee drinkers, 2) the low tremor scores in coffee drinkers are found in both the male and female subgroups, 3) coffee consumption is related to tremor in a dose-dependent manner, 4) the relationship between coffee consumption and tremor was statistically significant only in rest tremor, not in action tremor, and 5) the dose-dependent, inverse relationship between coffee consumption and tremor scores was significant only in the male subgroup.

The relationship between coffee consumption and tremor is controversial. Some people have previously stated that drinking coffee made their hands prone to tremor, and a small proportion of patients with essential tremor or PD thought that coffee worsened their tremor \[[@CR27]\]. However, caffeine only infrequently induces tremor in the general population, and it does not exacerbate pathological tremor \[[@CR27], [@CR28]\]. Although caffeine consumption is not correlated to tremor severity in patients with essential tremor \[[@CR29]\], currently, no studies exist on the association between caffeine and tremor in PD patients. Our study shows that coffee consumption could attenuate tremor severity in de novo PD patients.

Tremor may have distinct pathophysiology compared to bradykinesia and rigidity. Previous neuroimaging studies reported that patients with the tremor-dominant PD subtype show higher dopamine transporter binding than those with the AR subtype, whereas tremor severity does not correlate to striatal dopamine deficits \[[@CR30], [@CR31]\]. Furthermore, another neuroimaging study revealed the involvement of both the cerebellothalamic circuit and basal ganglia in PD tremor generation \[[@CR32]\]. Coffee is a major source of caffeine, which is the most widely consumed methylxanthine (1,3,4-trimethylxanthine) and is also a nonspecific adenosine A1/A2A receptor antagonist. Several studies have suggested that A2A receptor antagonists have a tremolytic effect in PD animal models \[[@CR10], [@CR33], [@CR34]\]. Although it is possible that caffeine has a symptomatic benefit on tremor, there might be other explanations, including the neuroprotective effect of caffeine, reverse causality (prodromal PD patients might have reduced desires for caffeine), or residual confounding by other factors (specific personality or changes in reward mechanism in PD) \[[@CR35]\]. In this study, we found that coffee consumption prior to diagnosis could influence tremor severity in de novo PD patients. Selective adenosine A2A antagonism through the modulation of basal ganglia function via opposing dopamine D2 receptors seems to be effective for the treatment of PD motor symptoms as a monotherapy or an adjunct therapy to dopaminergic agents \[[@CR36], [@CR37]\]. We believe that the effects of coffee on tremor severity in PD patients could be caused by the modulation of dopaminergic signaling even before clinical diagnosis. As such, future large prospective studies should investigate the therapeutic effects of coffee or adenosine A2A antagonists on tremor in PD. The findings from this study, therefore, suggest a potential therapeutic option for PD tremor, which responds less effectively to dopaminergic treatment than bradykinesia or rigidity.

In our study, the relationship between coffee consumption and tremor was significant only in rest tremor. One possible explanation is that rest tremor rather than action tremor is a typical symptom that reflects Parkinson's pathophysiology \[[@CR38]\]. However, these results could be related to the limitations of the UPDRS scoring system, because the total score of rest tremor is higher than that of action tremor.

A number of studies on the gender differences in PD patients were reported \[[@CR13]\]. For example, although female PD patients show a mild disease phenotype at first, they have a more aggressive disease progression and a higher probability of motor complications as the disease progresses \[[@CR13]\]. The impact of coffee and caffeine on PD risk and mortality also differs between genders \[[@CR5], [@CR12], [@CR14], [@CR15]\]. In fact, our study shows that the dose-dependent inverse association between coffee consumption and tremor severity is prominent in men but not in women. Such gender differences in PD have been partly explained by the effect of estrogen. Similar to our results, caffeine was reported to reduce the risk of PD, and its beneficial effect was prevented by the use of estrogen replacement therapy \[[@CR12]\]. In addition, caffeine was found to reduce the risk of PD in postmenopausal women without hormonal replacement therapy; however, increased PD risk was observed in estrogen users \[[@CR39]\]. Since estrogen has neuroprotective or neurotrophic effects and modulates the nigrostriatal dopaminergic system \[[@CR40]\], we suggest that estrogen modulates the effects of caffeine on the dopaminergic system and that a complex interaction between caffeine, estrogen, and dopamine exists in the basal ganglia system. Large prospective studies could elucidate the mechanism behind such observations.

In this study, we included de novo PD patients to ensure that the effects of medication would not represent a confounder. Additionally, we prospectively recruited patients with PD based on a registry to reduce the selection bias. Our study has several limitations. First, there were significant differences between coffee drinkers and non-coffee drinkers in demography, including age, sex, age at symptom onset, and formal education. Although, we adjusted for these variables in other analyses, it is possible that these differences could affect the relationship between coffee consumption and tremor. Second, we investigated the association between coffee consumption and motor symptoms in de novo PD patients only, without examining control or advanced PD groups. Further controlled studies would reveal a more precise association between tremor severity and coffee consumption in PD patients. Third, this study did not include information regarding the consumption of other caffeine-containing beverages. There is a possibility that other beverages containing caffeine can influence motor symptoms in PD patients. Fourth, we did not collect information on the menopausal status and hormonal replacement therapy in women. Therefore, the analysis of the association between coffee consumption and motor severity in the female subgroup according to the hormonal status was not possible.

Conclusion {#Sec10}
==========

Coffee drinkers had lower tremor scores when compared to non-coffee drinkers, and the coffee consumption was inversely related to tremor severity in a dose-dependent manner in de novo PD patients. These relationships were statistically significant only in rest tremor, not in action tremor. The effect of coffee consumption on tremor severity was gender-dependent, and it was significant only in men. Further investigations are needed to reveal the exact causal relationship between coffee consumption and tremor in PD patients.

ADL

:   Activities of daily living

ANCOVA

:   Analysis of covariance

AR

:   Akinetic-rigid

BDI

:   Beck Depression Inventory

K-MMSE

:   Korean versions of the Mini-Mental State Examination

mHY

:   modified Hoehn and Yahr scale

MoCA-K

:   Montreal Cognitive Assessment

MRI

:   Magnetic resonance imaging

NMSS

:   Non-Motor Symptoms assessment scale for Parkinson's disease

PD

:   Parkinson's disease

PIGD

:   Postural instability and gait disturbance

SD

:   Standard deviation

UPDRS

:   Unified Parkinson's Disease Rating Scale
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